CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
IV compared to remdesivir IV alone for the treatment of symptomatic COVID-19 in severely immunocompromised adult participants who a...
Phase 3
Durham, North Carolina, United States and 22 other locations
multi-center clinical trial (RCT) of SPI-1005 in adult subjects with positive PCR test for novel SARS-CoV-2 (nCoV2) and moderate symptoms of COVID...
Phase 2
Durham, North Carolina, United States and 6 other locations
multi-center clinical trial (RCT) of SPI-1005 in adult subjects with positive PCR test for novel SARS-CoV-2 (nCoV2) and severe symptoms of COVID...
Phase 2
Durham, North Carolina, United States and 6 other locations
vaccine for the prevention of symptomatic Coronavirus Disease 2019 (COVID-19).In order to represent a more recently circulating SAR...
Phase 2
Durham, North Carolina, United States and 144 other locations
seek to enroll immunocompromised patients with Lower Tract parainfluenza infection.It also contains a sub-study to enroll patients with severe COVID...
Phase 3
Durham, North Carolina, United States and 66 other locations
study treatment works in the study) of the study medicine (called nirmatrelvir/ritonavir) for potential treatment of coronavirus disease 2019 (COVID...
Phase 3
Chapel Hill, North Carolina, United States and 74 other locations
studies or substudies based on age group and prior history of COVID-19 vaccinations. All participants in each of the 5 sub-studies ...
Phase 2, Phase 3
Durham, North Carolina, United States and 114 other locations
the study vaccine (called COMIRNATY) for the potential prevention of COVID-19. This study is seeking participants who:1. Are age \<...
Phase 4
Durham, North Carolina, United States and 31 other locations
against infection with SARS-CoV-2, the novel coronavirus causing COVID-19 disease. The investigational vaccine, MV-014-212, is a li...
Phase 1
Raleigh, North Carolina, United States and 1 other location
This Phase 2/3 study is a multi-portion design to confirm that the chosen formulation and dosing regimen of CoVLP has an acceptable immunogenicity an...
Phase 2, Phase 3
Raleigh, North Carolina, United States and 90 other locations
Clinical trials
Research sites
Resources
Legal